Hikal Ltd banner

Hikal Ltd
NSE:HIKAL

Watchlist Manager
Hikal Ltd Logo
Hikal Ltd
NSE:HIKAL
Watchlist
Price: 211.46 INR 10.9%
Market Cap: ₹26.1B

Relative Value

The Relative Value of one HIKAL stock under the Base Case scenario is hidden INR. Compared to the current market price of 211.46 INR, Hikal Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HIKAL Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

HIKAL Competitors Multiples
Hikal Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Hikal Ltd
NSE:HIKAL
23.5B INR 1.5 258.2 12.6 37.5
US
Eli Lilly and Co
NYSE:LLY
960.1B USD 14.7 46.5 31.4 33.4
US
Johnson & Johnson
NYSE:JNJ
579.4B USD 6.2 21.6 15 18.4
CH
Roche Holding AG
SIX:ROG
281.2B CHF 4.6 29.9 12.6 14.8
UK
AstraZeneca PLC
LSE:AZN
228.3B GBP 5.5 33.7 16 23.5
CH
Novartis AG
SIX:NOVN
235.6B CHF 5.4 21.7 13.4 17.2
US
Merck & Co Inc
NYSE:MRK
295.4B USD 4.5 16.2 10.1 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.2 9.7 11.4
US
Pfizer Inc
NYSE:PFE
158B USD 2.5 20.3 7.5 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
122.2B USD 2.5 17.3 6.8 8.7
P/E Multiple
Earnings Growth PEG
IN
Hikal Ltd
NSE:HIKAL
Average P/E: 47.9
258.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.5
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.6
7%
3.1
CH
Roche Holding AG
SIX:ROG
29.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
33.7
38%
0.9
CH
Novartis AG
SIX:NOVN
21.7
15%
1.4
US
Merck & Co Inc
NYSE:MRK
16.2
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
7%
1.9
US
Pfizer Inc
NYSE:PFE
20.3
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Hikal Ltd
NSE:HIKAL
Average EV/EBITDA: 42.6
12.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
18%
1.7
US
Johnson & Johnson
NYSE:JNJ
15
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
16
10%
1.6
CH
Novartis AG
SIX:NOVN
13.4
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.1
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.7
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Hikal Ltd
NSE:HIKAL
Average EV/EBIT: 92.9
37.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
23.5
23%
1
CH
Novartis AG
SIX:NOVN
17.2
12%
1.4
US
Merck & Co Inc
NYSE:MRK
11.8
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
8%
1.4
US
Pfizer Inc
NYSE:PFE
10.1
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-6%
N/A